SRPT Q1 2023 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$254M+20.2% YoY

Gross Profit

$218M86.2% margin

Operating Income

-$138M-54.5% margin

Net Income

-$517M-203.8% margin

EPS (Diluted)

$-5.86

QoQ Revenue Growth

-1.9%

Cash Flow

Operating Cash Flow

-$209M

Free Cash Flow

-$219M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$2.3B

Stockholders' Equity

$713M

Cash & Equivalents

$872M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$254M	$211M	+20.2%
Gross Profit	$218M	$179M	+21.8%
Operating Income	-$138M	-$87M	-58.9%
Net Income	-$517M	-$105M	-392.0%

Geographic Segments

UNITED STATES

$201M87%

Non-US

$31M13%